Quality of life assessment in patients treated with nasal corticotherapy for allergic rhinitis: A cohort study. (December 2020)

• Record Type: Journal Article
• Authors: Chaouki, A.; Mkhatri, A.; Bouhmadi, K. El; Rouadi, S.; Oukessou, Y.; Abada, R.; Roubal, M.; Mahtar, M.
• Is Part Of: Annals of medicine and surgery. Volume 60(2021)
• Page Start: 249
• Page End: 254
• Publication Date: 2020-12
• Subjects: Allergic rhinitis -- Corticosteroid therapy -- Quality of life assessment; Surgery -- Periodicals; Medicine -- Periodicals; General Surgery -- Periodicals; Education, Medical -- Periodicals; Periodicals; 617
• DOI: 10.1016/j.amsu.2020.10.043
• Languages: English
• ISSNs: 2049-0801

Abstract

Abstract: Introduction: Allergic rhinitis (AR) is a chronic nasal pathology induced by an inflammation of the mucous membranes due to a dependent IgE reaction following allergenic exposure. The main symptoms are rhinorrhea, nasal itching, nasal obstruction and sneezing bursts. It highly affects the patient quality of life (QoL) in many levels making it a public health issue. The aim of this study is to assess the QoL of patients with AR as well as the level of its improvement after nasal corticotherapy. Materials and methods: From June 2019 to February 2020, a prospective study was carried out based on the use of the validated Arabic version of the RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) on a cohort of AR patients to measure their QoL before and after three months of treatment by "Budesonide". Results: A total of 70 patients participated in the study with an average age of 39.54 years with a sex ratio of 0.60. Their total RQLQ score was up to 4.28, improved to 2.35 after treatment. Also, a statistically significant improvement in sub-scores was also observed (p < 0.001): activities (from 4.43 to 2.29), nasal symptoms (from 5.00 to 2.80), eye symptoms (from 3.38 to 1.80), practical problems (from 4.29 to 2.18), general problems (from 4.63 to 2.78) and emotional state (from 4.28 to 2.43). Conclusion: The RQLQ is a reliable tool to evaluate the QoL in AR patients, stating the negative influence of AR on patients daily life and the effectiveness of nasal corticosteroid treatment. Highlights: Allergic rhinitis (AR) highly affects the patient quality of life (QoL) in many levels making it a public health issue. The aim of this study is to assess the QoL of patients with AR as well as the level of its improvement after nasal corticotherapy. The Rhinoconjunctivitis Quality of Life Questionnaire, a reliable tool to evaluate the QoL, demonstrated the negative impact of AR on patients daily life and highly effectiveness of nasal corticosteroid treatment.